FeesSafety
Pluang+

Ripple CTO Emeritus David Schwartz remains active on Ripple's board and with his former team.

Others
03 Nov 2026, 14:47 WIB
Tokenpost
View Source
Neutral
Ripple CTO Emeritus David Schwartz remains active on Ripple's board and with his former team.

David Schwartz, Ripple's CTO Emeritus and one of the original architects of the XRP Ledger, revealed that he continues to serve on Ripple's board. He meets with his former team twice a month and occasionally visits Ripple offices to stay connected. Although he did not specify his exact board duties or discussion topics, his ongoing involvement suggests continued influence in Ripple's development and strategy.

David Schwartz's ongoing role with Ripple provides context for readers. For those tracking major cryptocurrencies on Pluang, 12 out of 50 rose while 37 fell. THETA was priced at Rp2.719 with a 2.54% decrease, ALGO rose 2.22% to Rp1.702, and TRX increased 2.13% to Rp5.900 as of Nov 03, 2026 19:03 WIB.

More News

Automatic FOUP Opener Market to reach $6.04B by 2032 with 5.36% CAGR driven by fab automation and contamination control

Automatic FOUP Opener Market to reach $6.04B by 2032 with 5.36% CAGR driven by fab automation and contamination control

The global Automatic FOUP Opener Market is projected to grow from USD 4.41 billion in 2026 to USD 6.04 billion by 2032, expanding at a CAGR of 5.36%. Growth is driven by increasing fab automation, stricter contamination control requirements, and dema...

Market News
Bullish
17 minutes ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
3 hours ago
Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
3 hours ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
3 hours ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App